wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q39198025-3B29C339-81E5-4A9D-BE74-3A28BCD63E22
Q39198025-3B29C339-81E5-4A9D-BE74-3A28BCD63E22
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39198025-3B29C339-81E5-4A9D-BE74-3A28BCD63E22
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.
P2860
Q39198025-3B29C339-81E5-4A9D-BE74-3A28BCD63E22
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39198025-3B29C339-81E5-4A9D-BE74-3A28BCD63E22
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e45985d4eb813eaf57aca33488adce5975aa876e
P2860
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)